GluK2 is a target for gene therapy in drug-resistant Temporal Lobe Epilepsy. Boileau C, Deforges S, Peret A, Scavarda D, et al. Ann Neurol 2023 Jun 21. doi: 10.1002/ana.26723.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Boileau C, Deforges S, Peret A, Scavarda D, et al. GluK2 is a target for gene therapy in drug-resistant Temporal Lobe Epilepsy. Ann Neurol 2023 Jun 21. doi: 10.1002/ana.26723.
PMID: 37341588